Background: Nurses play a substantial role in the prevention and management of chemotherapy-induced nausea and vomiting (CINV).
Objectives: This study set out to describe nurses’ roles in the prevention and management of CINV and to identify any gaps that exist across countries.
Methods: A self-reported survey was completed by 458 registered nurses who administered chemotherapy to cancer patients in Australia, China, Hong Kong, and 9 Latin American countries.
Results: More than one-third of participants regarded their own knowledge of CINV as fair to poor. Most participants (>65%) agreed that chemotherapy-induced nausea and chemotherapy-induced vomiting should be considered separately (79%), but only 35% were confident in their ability to manage chemotherapy-induced nausea (53%) or chemotherapy-induced vomiting (59%). Only one-fifth reported frequent use of a standardized CINV assessment tool and only a quarter used international clinical guidelines to manage CINV.
Conclusions: Participants perceived their own knowledge of CINV management to be insufficient. They recognized the need to develop and use a standardized CINV assessment tool and the importance of adopting international guidelines to inform the management of CINV.
Implications for Practice: Findings indicate that international guidelines should be made available to nurses in clinically relevant and easily accessible formats, that a review of chemotherapy assessment tools should be undertaken to identify reliable and valid measures amenable to use in a clinical settings, and that a CINV risk screening tool should be developed as a prompt for nurses to enable timely identification of and intervention for patients at high risk of CINV.
Author Affiliations: Peter MacCallum Cancer Centre and Faculty of Medicine, Dentistry, and Health Sciences, The University of Melbourne, Victoria, Australia (Drs Krishnasamy and Aranda and Mr Annab); Nethersole School of Nursing, Chinese University of Hong Kong, China (Dr Kwok-wei So); School of Nursing and Midwifery, Queensland University of Technology, Queensland, Australia (Dr Yates); School of Nursing, Pontificia Universidad Javeriana, Bogota, Colombia (Ms de Calvo); Merck & Co Inc, Whitehouse Station, New Jersey (Ms Wisniewski); Cancer Institute New South Wales, Sydney, Australia (Professor Aranda).
This study was supported through a collaboration between the International Society of Nurses in Cancer Care and Merck, Inc, through an unrestricted educational grant.
The authors have no conflicts of interest to disclose.
Correspondence: Meinir Krishnasamy, PhD, RN, Peter MacCallum Cancer Centre, St Andrew’s place, East Melbourne, Victoria, Australia 8006 (email@example.com).
Accepted for publication July 2, 2013.